Q4 2025 Phibro Animal Health Corp Earnings Call Transcript
Key Points
- Phibro Animal Health Corp (PAHC) reported a strong quarter with a 53% sales growth in the Animal Health segment and a 47% increase in adjusted EBITDA.
- The integration of the Zoetis medicated feed additive portfolio contributed significantly, with a 77% growth in the MFA and other portfolio.
- Nutritional specialties and vaccines showed solid gains, with increases of 11% and 21% respectively, highlighting the strength of PAHC's diversified portfolio.
- Full-year Animal Health sales rose 36%, with adjusted EBITDA up 53%, showcasing robust performance across the board.
- The company provided a positive outlook for fiscal year 2026, projecting net sales between $1.425 billion and $1.475 billion, and adjusted EBITDA of $225 million to $235 million, reflecting confidence in their growth trajectory.
- Increased SG&A expenses due to higher employee-related costs impacted the overall financial performance.
- Higher adjusted interest expenses partially offset the increased gross profit driven by sales growth.
- The legacy MFA business experienced a 4% decline in net sales due to timing of specific customer orders and strong performance in the previous year.
- Corporate expenses increased by $2.9 million, driven by higher employee-related costs and strategic investments.
- The company faces potential risks from tariffs and foreign currency fluctuations, which are not fully embedded in the guidance.
Hello, and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Phibro Animal Health Corporation fourth quarter and fiscal year 2025 results webcast and conference call. After the speaker's remarks, there will be a question-and-answer session (Operator Instructions).
I would now like to turn the conference over to Glenn David, Chief Financial Officer. Please go ahead.
Good day, and welcome to the Phibro Animal Health Corporation earnings call for our fiscal fourth quarter and full year ending June 30, 2025. My name is Glenn David, and I'm the Chief Financial Officer of Phibro Animal Health Corporation.
I'm joined on today's call by Jack Bendheim, Phibro's Chairman, President and Chief Executive Officer; Donny Bendheim, Director and Executive Vice President of Corporate Strategy; and Larry Miller, Chief Operating Officer.
Today, we will cover financial performance for our fourth
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
